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Abstract 44 
Purpose: 45 
CHD1 deletions and SPOP mutations frequently co-occur in prostate cancer (PCa) with 46 
lower frequencies reported in castration-resistant PCa (CRPC). We monitored CHD1 47 
expression during disease progression and assessed the molecular and clinical 48 
characteristics of CHD1 deleted/ SPOP mutated metastatic CRPC (mCRPC).  49 
Experimental Design: 50 
We identified mCRPC 89 patients who had hormone naive and castration resistant tumor 51 
samples available: these were analyzed for CHD1, PTEN and ERG expression by 52 
immunohistochemistry (IHC). SPOP status was determined by targeted next generation 53 
sequencing (NGS). We studied the correlations between these biomarkers and a) overall 54 
survival from diagnosis; b) overall survival from CRPC; c) duration of abiraterone treatment 55 
and d) response to abiraterone. Relationship with outcome was analysed using Cox- 56 
regression and Log-Rank analyses.  57 
Results: 58 
CHD1 protein loss was detected in 11 (15%) and 13 (17%) of HSPC and CRPC biopsies, 59 
respectively. Comparison of CHD1 expression was feasible in 56 matched, same patient 60 
HSPC and CRPC biopsies. CHD1 protein status in HSPC and CRPC correlated in 55 of 56 61 
cases (98%). We identified 22 patients with somatic SPOP mutations, with 6 of these 62 
mutations not reported previously in PCa. SPOP mutations and/ or CHD1 loss was 63 
associated with a higher response rate to abiraterone (SPOP: OR=14.50 p=0.001; CHD1: 64 
OR=7.30, p=0.08) and a longer time on abiraterone (SPOP: HR=0.37, p=0.002, CHD1: 65 
HR=0.50, p=0.06). 66 
Conclusion: 67 
SPOP mutated mCRPCs are strongly enriched for CHD1 loss. These tumors appear highly 68 
sensitive to abiraterone treatment.  69 
 70 
Translational Relevance: 71 
The genomic heterogeneity of prostate cancer has been elucidated, enabling the study of 72 
how genomic sub-classification of these diseases associates with treatment outcome. These 73 
studies have identified SPOP mutations as early events in prostate tumorigenesis that 74 
commonly associate with CHD1 loss, and define a sub-class of this disease. SPOP 75 
mutations have recently been reported to associate with increased androgen receptor 76 
signaling. We therefore hypothesized that prostate cancers with SPOP mutations would be 77 
highly sensitive to AR blockade, and addressed this with regards to abiraterone treatment in 78 
efforts to develop predictive biomarkers of response to therapy. Abiraterone is a CYP17A1 79 
inhibitor that improves survival from advanced prostate cancer. We found here that this 80 
subclass of prostate cancers has a very high sensitivity to AR signaling blockade with 81 
abiraterone, with most SPOP mutated/ CHD1 deleted cancers responding to this.  82 
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Introduction 84 
 85 
Adenocarcinomas of the prostate comprise a heterogeneous collection of malignancies with 86 
distinct molecular underpinnings. Linking molecular background to clinical outcome, i.e. 87 
tumor progression and response to therapy remains an unmet need in prostate cancers. So 88 
far, genomic alterations are still not validated as molecular markers for patient stratification 89 
for current standard treatments in this disease. This is partially due to the lack of well- 90 
annotated patient cohorts, which cover disease evolution from localized, hormone naïve 91 
disease to metastatic castration resistant prostate cancer (mCRPC).  92 
 93 
Deletions in the gene encoding the chromodomain helicase DNA binding protein 1 (CHD1) 94 
and mutations in the gene encoding the Speckle-Type POZ protein (SPOP) are among the 95 
most frequent genomic alterations in prostate cancer (up to 29%) (1-6). CHD1 is an ATPase- 96 
dependent helicase mediating a variety of biological processes including maintenance of 97 
open chromatin, DNA damage repair and transcription (7). SPOP is part of a E3-ubiquitin 98 
ligase complex that is involved in controlling protein stability of the androgen receptor (AR) 99 
and some of its transcriptional co-activators (8-10). In PCa, mutations specifically impact the 100 
MATH protein domain of SPOP leading to increased stability of its substrates and 101 
deregulation of diverse molecular pathways impacting transcription, invasion, genome 102 
instability and drug resistance (2, 10-14). Loss of CHD1 significantly co-occurs with 103 
mutations in SPOP (2, 4, 5). Patients bearing these genomic alterations form a molecular 104 
subclass of prostate cancer with increased androgen receptor (AR) transcriptional activity, 105 
absence of ERG rearrangements and specific epigenetic pattern (4). Importantly, a recent 106 
study of multiparametric magnetic resonance imaging (mpMRI) in localized PCa suggests 107 
that CHD1 deleted foci may associate with a less aggressive imaging phenotype (15). 108 
Whether and how CHD1 loss and SPOP mutation impact progression to lethal metastatic 109 
disease is, however, still unclear. Recent next generation DNA sequencing studies suggest 110 
significantly different CHD1 deletion and SPOP mutation frequencies when comparing 111 
localized PCa with metastatic castration-resistant prostate cancer (4, 5). This either suggests 112 
better outcome for these tumors to initial therapy or a more indolent clinical behavior. 113 
However these observations are difficult to interpret since disease molecular evolution during 114 
progression has not been monitored.  115 
 116 
Genomic sequencing studies have enabled the molecular stratification of PCa identifying 117 
diverse subclasses with the promise of developing novel therapeutic strategies to deliver 118 
more precise patient care and improving outcome. Abiraterone improves survival in men with 119 
mCRPC but the benefit derived varies substantially between patients (16). Limited 120 
information is available for improving patient selection for such therapies. Because CHD1 121 
deletions and SPOP mutations reflect a common molecular PCa subclass with increased AR 122 
activity, we evaluated the clinical outcome from these cancers hypothesizing that these 123 
tumors would be highly sensitive to abiraterone treatment.  124 
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Material and Methods 126 
Patient selection, clinical data and study design 127 
Biopsies from bone, lymph node and liver metastases were obtained from patients with 128 
metastatic-castration resistant prostate cancer treated at the Royal Marsden Hospital 129 
between 2010-2016 and that were a) fit enough to participate in a clinical trial and b) 130 
consented for next generation DNA sequencing analysis. All patients gave their written 131 
informed consent and were enrolled on institutional protocols approved by the Royal 132 
Marsden NHS Foundation Trust Hospital (London, UK) ethics review committee (reference 133 
no. 04/Q0801/60). CRPC biopsies were acquired between 2010 and 2016 in accordance 134 
with the ethical guidelines of the Helsinki declaration. Clinical data including response to 135 
treatment was retrospectively collected from electronic patient records. Patients received 136 
abiraterone treatment in UK centers between November 2006 and December 2015. 137 
Response to therapy was defined based on Response Evaluation Criteria in Solid Tumours 138 
(RECIST) version 1.1 criteria and/or PSA falls ≥50% from baseline (17). This study was 139 
designed as a case-control study with SPOP mutant patients being selected based on DNA 140 
sequencing data and being matched with unselected SPOP wild type patients as controls. 141 
 142 
Cell lines 143 
22Rv1 (ATCC®CRL-2505), PC-3 (ATCC®CRL-1435) and NCI-H660 (ATCC®CRL-5813) 144 
prostate cancer cell lines were purchased from ATCC and cultured according to the 145 
manufacturer’s protocol. CHD1 CRISPR clones were derived as described earlier (7).  146 
 147 
siRNA transfection 148 
siRNAs targeting CHD1 and non-targeting controls were purchased from Dharmacon 149 
(siGenome smartpool CHD1: M-008529-01-0005, siGenome smartpool non-targeting control: 150 
D-001206-13-05). siRNA oligonucleotides were transfected with lipofectamine 3000 (Life 151 
Technologies) at a final concentration of 100pmol and incubated for 48hrs. 152 
 153 
Immunoblotting 154 
22Rv1 isogenic CRISPR clones, siRNA transfected 22Rv1, PC-3 and NCI-H660 cells were 155 
harvested in RIPA buffer (Pierce, 89900) containing protease and phosphatase inhibitors 156 
(complete mini protease inhibitor cocktail tablets, Roche, 11374600). The soluble fraction 157 
was isolated using centrifugation and quantified by bicinchonininc acid assays (BCA) (Pierce, 158 
QG219588). Cell lysates were mixed with LDS sample buffer (Life Technologies, 1621149) 159 
and 30-50μg of total protein was loaded onto 4-12% gradient SDS acrylamide gels (Life 160 
Technologies, NP0322). Transfer to PDVF membrane (Millipore, IPV400010) was performed 161 
at 90V for 90 minutes at room temperature. Protein bands were detected using HRP- 162 
substrate (Millipore, WBLUC0500). Primary antibodies were anti-CHD1 rabbit monoclonal 163 
antibody (clone D8C2, Cell Signaling, 4351) and anti-GAPDH (clone 6C5, Millipore, 164 
MAB374). Secondary antibodies were anti-rabbit and anti-mouse horseradish peroxidase- 165 
conjugated whole antibody from sheep (GE, NA934V and NXA93). 166 
 167 
Immunohistochemistry 168 
Immunohistochemistry was performed on 3μM formalin-fixed and paraffin-embedded (FFPE) 169 
tissue sections. Heat based antigen retrieval was performed by boiling the tissue sections in 170 
pH6 citrate buffer (TCS Biosciences Ltd., HDS05, 1:100 dilution) for 18 minutes using a 171 
microwave. CHD1 immunostaining was done on the Launch i6000 IHC autostainer using a 172 
1:50 dilution of primary antibody binding CHD1 (Cell Signaling, #4351) for 1hr. Visualization 173 
of antibody binding was achieved using the Novolink polymer detection method (Leica, 174 
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RE7200-CE). To avoid false negative results, we defined endothelial cell CHD1 expression 175 
as a necessary internal control for samples to be included in the analysis. 176 
Immunohistochemistry for PTEN and ERG was done as reported previously (18, 19). Tumor 177 
content, morphology and intensity of protein expression were evaluated by a pathologist 178 
(D.N.R.). H-score was defined as described earlier (18). The cut off for CHD1 protein loss 179 
was define as H-score ≤5. 180 
Fluorescence in situ hybridization 181 
FISH for assessing CHD1 copy number status in formalin-fixed and paraffin-embedded 182 
tumor tissue was performed as described previously (18). The probes were: CHD1 (RP11- 183 
58M12, chr. 5q21) and reference (RP11-429D13, chr. 5p13.1). Probes were amplified using 184 
the GenomiPhi v3 DNA amplification kit (Illustra, 25-6601-24) and directly labeled with CY3 185 
(CHD1) and CY5 using the Bioprime DNA labeling system (Thermo Fisher Scientific, 186 
18094011). Fluorescence images were taken using the Bioview Duet imaging system and 187 
copy number status of at least 50 non-overlapping tumor cell nuclei were determined by a 188 
pathologist (D.N.R). 189 
DNA sequencing 190 
DNA isolation: DNA from tumor tissue biopsies was extracted using the QIAamp DNA FFPE 191 
Tissue kit (Qiagen, Venlo, Limburg, Netherlands), quantified by Quant-iT Picogreen double- 192 
stranded DNA (dsDNA) Assay Kits (Invitrogen, ThermoFisher Scientific Co). The Illumina 193 
FFPE QC kit (WG-321-1001) was used for DNA quality control tests. 194 
Targeted sequencing: Libraries were prepared using a customized Generead v2 DNAseq 195 
Panel (Qiagen) consisting of 113 genes including SPOP as previously described (20, 21). 196 
Libraries were read on the Illumina MiSeqTM platform.  197 
Sequence alignment: FASTQ files were generated using the Illumina MiSeq Reporter 198 
v2.5.1.3. Sequence alignment and mutation calling was performed using BWA tools and the 199 
GATK variant annotator by the Qiagen GeneRead Targeted Exon Enrichment Panel Data 200 
Analysis web Portal. 201 
Bioinformatic analysis 202 
Mutation burden: The mutation burden was estimated from targeted next generation 203 
sequencing (NGS) panel data after filtering out of spurious and germline variants using 204 
methods reported previously (22). Genetic variants were called using the GATK pipeline 205 
(23). Low quality variants were removed (haplotype score >200, mapping quality<40, 206 
coverage depth <60, alternative allele <5% of reads, multi-allelic calls, indels, known poorly 207 
sequenced sites). Variants were then annotated using Oncotator (version 1.8.0)(24). 208 
Germline variants were defined when the allele frequency was >5% in our cohort or in two or 209 
more public databases (ExAC) (25), 1000 Genomes (The 1000 Genomes Project 210 
Consortium) (26) and dbSNP (27), or with more than 99.9% of the reads being the alternate 211 
allele. These germline variants were filtered out. Finally, point mutations described as 212 
somatic in the COSMIC database (28) at least 10 times or more were then ‘added’ back into 213 
the mutation count. 214 
Copy number burden: Following assessment of copy number variation from targeted NGS, 215 
we calculated copy number burden as the proportion of evaluable genes (n=99) bearing any 216 
detectable change, i.e. a log2 ratio of greater or less than 0.4 and -0.4 respectively (21). 217 
Samples were included in the analysis if the total read count was >500K, >95% of properly 218 
paired reads, >99.9% reads on target and IQR >0.8. 219 
Shannon Index: Given counts of FISH probes for minimum 50 individual cells on a per- 220 
sample basis, we calculated inter-cellular diversity by classifying each cell by the state of 221 
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both probes, totaling the number of each class, and applying the R package Vegan (v.2.4.4) 222 
to generate the Shannon-Weaver diversity index H.  223 
Statistical analysis 224 
Clinical characteristics at diagnosis (age, Gleason score, metastatic disease), and 225 
treatments received, were compared by CHD1 status at CRPC using Wilcoxon Rank-Sum 226 
tests or Fisher's Exact test if categorical. Baseline levels of PSA, hemoglobin, alkaline 227 
phosphatase, lactate dehydrogenase and albumin at the start of abiraterone treatment were 228 
compared by CHD1 and SPOP status at CRPC using t-tests or Wilcoxon Rank-Sum tests if 229 
considered to be non-normally distributed. Data on castration-resistance was determined 230 
retrospectively from patient’s medical records. The change in CHD1 H-Score in patient 231 
matched HSPC and CRPC samples was compared using the Wilcoxon matched-pairs 232 
signed-ranks test. Overall survival (OS) from diagnosis, CRPC and the start of abiraterone 233 
treatment was compared by CHD1 and SPOP status using Kaplan-Meier plots. Univariate 234 
Cox models were used to evaluate the association of metastatic disease at diagnosis, SPOP 235 
mutation, CHD1 negativity and ERG expression at CRPC with OS from diagnosis, time on 236 
abiraterone and time from start of LHRH to CRPC. Univariate logistic regression analyses 237 
also evaluated the association of these characteristics with response to abiraterone, defined 238 
as radiographic response according to the Response Evaluation Criteria in Solid Tumours 239 
1.1 (RECIST) and/or a ≥50% fall in PSA from baseline (17). All analyses were conducted 240 
using Stata v13.1. 241 
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Results 243 
Establishing a CHD1 immunohistochemistry assay 244 
To determine the frequency of CHD1 protein loss across a spectrum of clinical states, we 245 
established and validated an immunohistochemistry (IHC)-based assay for formalin-fixed 246 
and paraffin-embedded (FFPE) tissue. We first evaluated FFPE embedded human prostate 247 
cancer cell lines that either had an amplification (PC-3) or deletion (NCI-H660) of CHD1 248 
confirmed by fluorescence in situ hybridization (FISH) (Figure 1A). To further ensure the 249 
specificity of the antibody, we depleted CHD1 in the CRPC cell line 22Rv1 transiently by 250 
siRNA as well as stably by CRISPR/ CAS9. Western blot analysis using the same CHD1 251 
antibody revealed a major decrease of CHD1 protein after siRNA and CRISPR/CAS9 252 
treatment (Figure 1B). The loss of CHD1 after CRISPR/CAS9 knockout in this isogenic 253 
model was further validated in FFPE embedded cells (Figure 1B). Lastly, we implemented 254 
the IHC assay in human tumor biopsies from 44 PCa patients (12 HSPC, 32 CRPC) 255 
representative of the most common sites of disease (13 bone, 9 lymph node, 5 liver, 3 soft 256 
tissue and 2 TURP biopsies) and compared CHD1 expression with gene copy number 257 
determined by FISH. Overall, 3/44 (7%) had loss of both CHD1 expression by IHC as well as 258 
gene loss by FISH. CHD1 protein expression by IHC and gene copy number status by FISH 259 
were strongly associated (Figure 1C, 1D).  260 
Molecular features of CHD1 deleted CRPC 261 
To explore the molecular features of CHD1 deleted lethal prostate cancer we selected 89 262 
patients for whom we had CRPC biopsies (Supplementary Figure 1A) enriching this cohort 263 
for CHD1 loss CRPC by including tumors with known SPOP mutations based on data from 264 
prior molecular characterization studies. We performed IHC for CHD1 in paired, same 265 
patient, CRPC and HSPC biopsies from these 89 subjects. The IHC data were analyzable for 266 
73 (82%) and 83 (93%) HSPC and CRPC biopsies, respectively. We identified 11 (15.1%) 267 
and 13 (16.9%) HSPC and CRPC biopsies, respectively, with complete loss of CHD1 protein 268 
(Figure 2A). Targeted or whole exome DNA sequencing data were available for 71 (79.7%) 269 
patients (CRPC biopsies: n=69, HSPC biopsies: n=2), with 22 of these carrying a mutation 270 
that affect SPOP (Figure 2B). We identified 6 mutations, which have not been previously 271 
described in PCa before, including one (p.A187T) located in the BTB domain in an area 272 
reported to be necessary for homodimerization (Figure 2B, Supplementary Table 1): two of 273 
these 6 mutations were located in residues (E50, R121) previously associated with 274 
endometrial cancer (29). The overall distribution of altered residues was, however, similar to 275 
other CRPC cohorts resulting in two distinct mutational hotspots in the MATH domain 276 
(Supplementary Figure 2B). Loss of CHD1 and/ or SPOP mutation (CHD1Loss/SPOPMUT) was 277 
found in a total of 22 patients (24.7%). All CHD1 loss cases that could be analyzed by 278 
targeted sequencing (11 out of 13 could be sequenced), had an SPOP mutation (p<0.0001) 279 
(Table 1, Figure 2A). We performed ERG IHC analysis in our CRPC cohort and confirmed a 280 
mutually exclusive relationship between SPOP mutations and CHD1 loss and ERG 281 
overexpression (p<0.001 for SPOP; p=0.003 for CHD1) (Figure 2A). Prior genomic studies in 282 
localized PCa have suggested a synthetic lethal relationship between CHD1 loss and loss of 283 
the tumor suppressor PTEN. Surprisingly, our analysis identified 2 cases (2.4%) of combined 284 
CHD1 and PTEN protein loss suggesting that although the majority of CHD1Loss/SPOPMUT 285 
tumors in our cohort do not have PTEN loss, certain genomic backgrounds tolerate the 286 
concurrent loss of these two proteins (Figure 2A, Supplementary Figure 2A). To investigate 287 
the impact of SPOP mutations on genome stability in CRPC we estimated mutation (SNV) 288 
burden and copy number burden based on targeted NGS data from 46 analyzable CRPC 289 
samples. SPOP mutation did not associate with differences in SNV burden (Figure 2C). 290 
However, SPOP mutation associated with increased copy number changes (p=0.013) 291 
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identified by targeted NGS similar to what we previously reported using whole genome DNA 292 
sequencing for localized PCa (Figure 2D). 293 
CHD1 status during disease progression  294 
Since CHD1 loss co-occurred with SPOP mutations we hypothesized that the CHD1 gene 295 
locus is under selective pressure throughout the evolution of SPOP mutant PCa. To estimate 296 
the stability of the CHD1 gene locus during tumor evolution we evaluated copy number 297 
states at a single-cell level using fluorescence in situ hybridization (FISH) in matched HSPC 298 
and CRPC biopsies. For this purpose we determined copy number combinations of CHD1 299 
(5q21) and reference probes (5p13.1) in 4266 single cells in matched HSPC and CRPC 300 
biopsies from 36 patients and calculated the Shannon index (Figure 2E,F). This allowed us 301 
to perform a quantitative measurement of chromosome 5 copy number diversity at single cell 302 
level for each biopsy. This analysis indicates that PCa commonly has various degrees of 303 
intratumour genomic heterogeneity at 5p/5q with some dramatic outliers. However, SPOP 304 
mutant lethal PCa showed a significantly lower clonal diversity at chromosome 5 (Figure 2F, 305 
Supplementary Figure 2D,E) (HSPC: p=0.018, CRPC: p=0.0025). When comparing the 306 
Shannon index between HSPC and CRPC patient-matched biopsies, no significant changes 307 
of genomic clonal diversity occurred with progression on androgen deprivation therapy (ADT) 308 
from HSPC to CRPC (Figure 2F) suggesting that the loci containing CHD1 are a) an 309 
important driver locus in SPOP mutant tumors and b) do not succumb to therapy-induced 310 
selection pressure. Thus, our analyses of patient-matched HSPC and CRPC biopsies from 311 
patients that developed lethal metastatic CRPC do not indicate a systematic depletion of 312 
CHD1 negative tumor clones during progression on ADT.  313 
To evaluate whether CHD1 protein expression changes during disease progression and 314 
development of resistance to ADT, we compared patient-matched HSPC and CRPC 315 
biopsies. Overall, 56 pairs of matched, same patient, HSPC and CRPC samples were 316 
available for CHD1 expression evaluation by IHC. When categorizing our samples into CHD1 317 
IHC negative and CHD1 IHC positive we found that there was no change in CHD1 318 
expression status between the matched tumor samples confirming our hypothesis that CHD1 319 
loss is under selective pressure during tumor progression; 55 out of 56 analyzable samples 320 
(98%) maintained their CHD1 status (Figure 2E). However, we found that overall, CHD1 321 
expression level increases with progression from HSPC to CRPC in CHD1 IHC positive 322 
cases (p=0.010) (Supplementary Figure 2C). Tumors with CHD1 loss of protein expression 323 
had no detectable tumor cells expressing CHD1. 324 
The CHD1 loss /SPOP MUT subclass and outcome from abiraterone  325 
We investigated if this molecular subtype of prostate cancer, defined by CHD1 loss and 326 
SPOP mutations (CHD1Loss/SPOPMUT) impacts clinical outcome. We evaluated the 327 
prognostic value of CHD1 loss and SPOP mutation and found no significant association with 328 
overall survival (OS) from diagnosis for either variable (Table 2). As previously reported, we 329 
also found no association between ERG expression, detecting ERG rearrangements, and 330 
OS (Table 2). We also analyzed the performance of known prognostic variables including 331 
presence of metastasis at diagnosis, which associated with shorter OS (p=0.002). 332 
Furthermore, we did not find any association between CHD1Loss/SPOPMUT and time to 333 
resistance to androgen deprivation therapy by LHRHa (Table 2). We found no association of 334 
CHD1Loss/SPOPMUT with OS from CRPC (Figure 3A). However, we speculated that there 335 
might be a better response to second line treatments such as abiraterone since preclinical 336 
data suggest a direct impact of SPOP on AR protein stability and signaling (8, 10, 12). We 337 
found that SPOP MUT patients respond better to abiraterone when considering 50% PSA falls 338 
(SPOP: p=0.03) and are less likely to progress (OR=14.50, p=0.001). Moreover, SPOP 339 
mutations are associated with longer median duration of abiraterone treatment (SPOP: 340 
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HR=0.37, p=0.002). Similar trends were observed for CHD1 when considered as individual 341 
variable although not reaching statistical significance (absence of progression: OR=7.30, 342 
p=0.08; abiraterone treatment duration: HR=0.50, p=0.06) (Table 2, Figure 3B,C, D; 343 
Supplementary Figure 3A-C, Supplementary Table 2). In summary, our data suggest that 344 
CHD1Loss/SPOPMUT patients might respond better to abiraterone. These data need to be 345 
validated now in samples from randomized phase III clinical trials.  346 
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Discussion 348 
Herein we describe key molecular features of CHD1 deleted/ SPOP mutant mCRPC showing 349 
that SPOP mutations and CHD1 loss associate with a higher likelihood of benefit from 350 
abiraterone therapy. CHD1 loss significantly associated with SPOP mutations, while ERG 351 
rearrangements, as detected by ERG protein expression inversely correlated with CHD1 loss 352 
and SPOP mutation suggesting that these genomic loci underlie selective pressure during 353 
progression to PCa. We report PTEN loss largely in CHD1 and SPOP wildtype backgrounds 354 
in mCRPC as reported for localized PCa but describe two patients with combined loss of 355 
CHD1 and PTEN suggesting that a synthetic essential relationship between these two 356 
proteins is not universal. Similar to previous reports most of the SPOP mutations identified 357 
affected the SPOP-MATH domain, which is responsible for the binding of protein substrates. 358 
When comparing these mutations with other cohorts, we identified a similar distribution with 359 
two major mutational hotspots including the residues Y83-F102 and F125-F133. Surprisingly, 360 
we also identified for the first time several SPOP mutations unreported in previous 361 
systematic prostate cancer studies including E50K, S105F, Q120R, R121P, G148E and 362 
A187T: these included two mutations affecting residues located in a less well-characterized 363 
portion of the MATH domain previously described in endometrial cancer. Whether these 364 
represent distinct functional impact unique to CRPC, or mechanistically have distinct 365 
substrate binding specificity, will need to be elucidated in future studies. 366 
 367 
Recent genomic studies in prostate cancer suggested a decreased frequency of SPOP 368 
mutations in mCRPC when compared to localized disease (8% versus 11%) (4, 5). The 369 
frequency of CHD1 homozygous loss was reported to be 4.7% versus 9% in mCRPC versus 370 
localized disease. It has been suggested that CHD1Loss/SPOPMUT tumors are generally less 371 
aggressive in nature and that perhaps these data indicate a decreasing frequency of this 372 
sub-type in mCRPC. However, our analysis in same patient, matched, treatment-naïve and 373 
mCRPC biopsies indicate that the frequency of CHD1 deletion does not change significantly 374 
with disease progression to mCRPC although we cannot completely exclude subclonal 375 
differences at 5q21 at a single cell level. Overall, our data indicate that this genotype is 376 
present from diagnosis and that there is no systematic selection generated by ADT, 377 
suggesting that the difference between the TCGA and SU2C series was most likely related 378 
to patient selection and not tumor evolution. 379 
 380 
Despite the in-depth molecular characterization and sub-classification of prostate cancer, 381 
there is currently limited understanding of how this impacts benefit from established 382 
treatments including abiraterone. A detailed understanding of the molecular characteristics of 383 
the prostate cancers sensitive or resistant to these drugs is urgently needed to help minimize 384 
overtreatment with inactive drugs. We describe here that SPOP mutant and CHD1 IHC 385 
negative mCRPC respond substantially better and longer to abiraterone when compared to 386 
mCRPC that lack these alterations. Prospective clinical trials are now needed to validate this 387 
differential response to abiraterone in this subclass of PCa. Considering the early onset of 388 
these alterations in the history of PCa, SPOP mutation/ CHD1 loss may function as positive 389 
predictive biomarkers for abiraterone therapy. 390 
 391 
This study does, however, have limitations since it is a retrospective, single center study 392 
conducted with an intentional selection bias to enrich for SPOP mutated PCa. These may 393 
limit translating these results to a general unselected population of prostate cancer patients. 394 
The impact of SPOP/CHD1 status on abiraterone treatment outcome now needs prospective 395 
validation. 396 
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Figure legends 410 
Table 1: Demographic and clinical characteristics of patients in this cohort. 411 
 412 
Table 2: Summary of univariate statistical analyses evaluating the association of CHD1 loss 413 
or SPOP mutation with response to LHRHa and abiraterone. 414 
 415 
Figure 1: Development and validation of CHD1 immunohistochemistry assay.  416 
A) Micrographs (20x) of formalin-fixed and paraffin-embedded (FFPE) prostate cancer cells 417 
negative (NCI-H660) or positive for CHD1 analyzed by CHD1 immunohistochemistry (top) 418 
and fluorescence in situ hybridization (FISH) (below). Signals from the FISH probes (CHD1: 419 
red; reference probe: green). B) Knockdown of CHD1 by siRNA or CRISPR/CAS9 decreases 420 
CHD1 protein levels in 22Rv1 cells by Western Blotting (left) and IHC on FFPE embedded 421 
cells using the same antibody as in A. C) Correlation of CHD1 copy number and expression 422 
level in 44 prostate cancer samples. Numbers for HSPC and CRPC are indicated. Protein 423 
expression was summarized as H-scores. p=0.002, one way Anova. D) Micrographs of 424 
representative examples of CHD1 loss (top) and CHD1 normal (below) by IHC (20x) and 425 
FISH (60x). Signals from the FISH probes (CHD1: green; reference probe: red). 426 
 427 
Figure 2: Molecular characterization of the CRPC cohort. 428 
A) Oncoprint summarizing CHD1, ERG and PTEN protein expression as well as SPOP 429 
mutation status in mCRPC biopsies from 89 patients. B) Lollipop blot representing the 430 
location of the affected amino acid changes in the SPOP protein corresponding to the 22 431 
identified mutations. C-D) Genomic features of SPOP mutant CRPC estimated by a targeted 432 
NGS assay (n=46). The levels of mutational burden do not change in SPOP mutant CRPC 433 
(p=0.1) (C). Copy number burden estimated by the percentages of genes affected are 434 
significantly higher in SPOP mutant CRPC compared with SPOP wildtype disease (p=0.013) 435 
(D). p-values were calculated using unpaired t-test. E) Workflow describing how the Shannon 436 
Index was calculated. We counted the signals from a dual FISH assay containing probes for 437 
5p and 5q on a single-cell level for each patient. FISH probes are indicated by red and green 438 
dots in the cell nucleus (blue). Different cell populations are then defined by possible probe 439 
combination reflecting the diversity of copy number differences at these genomic loci per 440 
tumor cell. The frequency of these different cell populations in a given biopsy reflects 441 
population diversity, which is estimated using the Shannon Index. F) SPOP mutant tumors 442 
have a significantly lower mean Shannon Index than SPOP wildtype tumors in both HSPC 443 
and CRPC biopsies (HSPC: p=0.018, CRPC: p=0.0025). Mean Shannon Indexes for each 444 
subclass do not change from HSPC to CRPC. p-values were calculated using unpaired t- 445 
test. n=36 G) CHD1 protein level in HSPC and CRPC biopsies. Heatmap summarizing CHD1 446 
expression status (loss versus normal) in 56 patient-matched paired biopsies from HSPC 447 
and CRPC. Blue indicates protein loss. Grey indicates protein expression. 448 
 449 
Figure 3: Association of CHD1 loss and SPOP mutation with clinical outcome. A) 450 
Kaplan Meier curve summarizing overall survival (OS) of SPOPMUT versus SPOPWT tumors 451 
from CRPC in this cohort. SPOP mutation is not prognostic. B, C) Kaplan Meier curves 452 
showing increased survival from start of abiraterone (B) and time on abiraterone (C) in 453 
SPOP mutant tumors. D) Waterfall plot showing increased PSA responses from start of 454 
abiraterone in SPOPMUT versus SPOPWT tumors. Each bar represents PSA nadir from start of 455 
treatment for an individual patient. Dashed line indicates PSA fall by 50%. PSA nadir data 456 
were available for 37 patients with known SPOP status. 457 
 458 
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Table 1 Demographic and clinical characteristics of patients 
 
 
 
 
 
 
Overall (n=89) 
Lacking CHD1 IHC n=6 (6.7%) 
CHD1 negative in CRPC 
n=13 (14.6%) 
CHD1 positive in CRPC 
n=70 (78.7%) 
P-value 
Age at diagnosis, years (mean(SD)) 62.7 (6.8) 59.9 (13.1) p=0.461 
Gleason at diagnosis  
2 (15%) 
 
5 (7%) 
 
p=0.712 
6 
7 2 (15%) 16 (23%) 
8-10 8 (62%) 44 (63%) 
NA 1 (8%) 5 (7%) 
Metastasis at diagnosis  
5 (39%) 
 
43 (61%) 
 
p=0.142 
M0 
M1 8 (62%) 27 (39%) 
PSA at diagnosis, ln(µg/l) (mean (SD)) 4.8 (1.6) 5 (1.6) p=0.821 
Treatments for CRPC  
11 (85%) 
9 (69%) 
 
64 (93%) 
62 (90%) 
 
p=0.312 
p=0.072 
Docetaxel 
Abiraterone 
 
 
 
 
 
 
 
 
 
 
1T-test 
2Fisher ’s Exact Test 
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Table 2 
 
 
 
Overall Survival from Diagnosis Univariate HR 95% CI p-value 
Metastatic at diagnosis 2.07 1.32-3.24 0.002 
SPOP mutation at CRPC 0.80 0.46-1.38 0.43 
CHD1 negative IHC at CRPC 0.81 0.42-1.58 0.54 
ERG at CRPC 1.14 0.72-1.78 0.58 
Time on Abiraterone Univariate HR 95% CI p-value 
Metastatic at diagnosis 1.00 0.63-1.60 0.99 
SPOP mutation at CRPC 0.37 0.20-0.69 0.002 
CHD1 negative IHC at CRPC 0.50 0.25-1.02 0.06 
ERG at CRPC 1.25 0.77-2.02 0.37 
Time from start LHRH to CRPC Univariate HR 95% CI p-value 
Metastatic at diagnosis 2.11 1.36-3.28 0.001 
SPOP mutation at CRPC 1.13 0.68-1.87 0.64 
CHD1 negative IHC at CRPC 0.86 0.44-1.69 0.66 
ERG at CRPC 1.16 0.75-1.79 0.52 
Response to Abiraterone Univariate OR 95% CI p-value 
Metastatic at diagnosis 0.72 0.29-1.80 0.49 
SPOP mutation at CRPC 14.50 2.92 -71.94 0.001 
CHD1 negative IHC at CRPC 7.30 0.82-65.11 0.08 
ERG at CRPC 0.71 0.28-1.82 0.47 
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